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tioii with porin deficiency In our strains no such inechanism is  
present. We conclude that resistaiice in the pre-therapy strain is partly 
due to impermeability of the outer membrane, which is still enforccd 
111 the po\t-therapy strain 
1 1  Sequence analysis of the ARI-1 beta-lactamase 
H.M. Ilonald, W. Scaife, S.G.B. Aniyes, H.K. Young. Iliiiiwsity of' 
Dirirdn~, Biolo'qiranl St-iriircs, Drmfec, I K  
Objectives: To dcterrnine the sequence ofthe ARI-1 beta-lactamate 
respoiisible for plasmid-encoded resistance to imipeneiu in the 
clinical isolate of .4rinraibnrtcr haitmurrnii strain 6B92. 
Methods: The  AKI-I beta-lactanlase was extracted and part~ally 
purified by anion exchange and gel exclusion chromatography. 
Purified enzyme was separated by polyacrylaniide gel electrophoresis 
and the first 70 ainino acids at the N-terminus were determined by 
Edman degradation, enabling a degcnerate oligonucleotide probe to 
be designed. This probe was used to detect clones containing the 
6hAKI-1 gene in a DNA librarv prepared froiu the imipenem 
resistance plasmid of .4. he~rmannii strain 6892. DNA sequences were 
determined using an ABI PKISM 377 Automated DNA Sequencer. 
Results: The nucleotide sequence of the hlaARI-1 gene showed 
some honiology to the Bb7OXA-5 gene of Psrudomonns arrtr'qinosa. In 
addition, comparisoii of the deduced amino acid sequence with 
sequences held in the SWISSPROT database revealed moderate 
(35'!6) honiology of the AKI-I eiizynie with CIXA-7, OXA-10 and 
OXA-11 in addition to OXA-5. The beta-lactaniase active site S-T- 
F-K and the conserved triad I<-T-C, characteristic of c1.m D beta- 
lactmiases, we]-e identified. 
Conclusions: The  ARI-1 enzyme, responsible for imipenem 
resist.iiice in '4. Imumanirii 6B92, appears to he related to the OXA 
class I> beta-lactanlaws 
A new strategy to limit R-lactamase induction 
in Enterobacter cloacae 
I>. Pfeifle, I. Wiegand, L1. Wiedeiiianii. C h i i t w j i t y  Roirrr, 
Pliarnraxrf ,  14fikrohiolo~qie, Boiiii, ~ ~ ~ r n z a r r y  
Objectives: Eiiferohartrr iloacac produces a cephalosporinase (AmpC) 
which is iiiducible by p-lactaiii antibiotics. P-Lactamase can also be 
constitutively or semi-constitutively overproduced when the amidase 
ArnpD is modified. P-Lactaiiia\e expression appears to be regulated 
by the level of 'inhydi-oniiiropeptides (aM\), especially by the 
anhydroniuraniylpentapeptide in the cytoplasm. The aMs are releatrd 
by the lytic tranrglyco\ylases from the peptidoglycan. Inhibition of 
these enzymes should stop p-lactmiase induction. One of these lytic 
transglycosylases. Slt 7(1, plays an iniportaiit role in p-lactaniase 
induction and can be inhibited by bulgecin 
Methods: E.  ~-/oarae strains were induced with strongp-lactaiiiase 
inducers and in combinmoii with bulgecin. P-Lactamase activity was 
quantified photometrically. MIC\ for /%lactam antibiotics alone and 
in combination with bulgecin were measured by the broth micro- 
dilution method. High-perforniaiice liquid chroiriatogrdphy analyw 
was used to measure the release of aMs froin the peptidoglycan in 
combiiiation with bulgecin 
Results: Inhibition of the Slt 70 by bulgecin stops P-lactanlase 
induction in E. clmoie wild types m d  in hyperinducible iiiutants. I n  
mutants with constitutive p-lactanuse overproduction, p-lactaniase 
activity decreases. Also, in all tested E .  rloarae strains the MlCs o fp -  
lactaniase-susceptible B-lactani antibiotics decrease 
Conclusion: Inhibition ofthe lytic transglycosyla\ec, especially Slt 
decrease of MlCs 7(1, can stop p-lactamase induction and result in 
of ampC _-lactaiiiase-susceptible fi-lactani antibiotic-s. 
Cloning and nucleotide sequence analysis of a 
gene encoding the AmpC P-lactamase in 
Acinetobacter baumannii 
G. Bou Arevalo, G. Cervero, J. Martinez-Beltrin. Hmpird  Karti6ir y 
Cyjal, hlicr~~bioluyy, R t d r i d ,  S p w r  
Objectives: To clone and sequence the gene encodirig the AmpC 
p-lactamase of "kir2i1fobdfrcr buitnianirii 
Methods and results: An '4. bniri~inrriiii main showing rc\i\tmce 
to all p-lactani antibiotics was studied. By isoelcctrofocusing (IEF) of 
the sonicated extract, three P-lactama\es appexed: pla\iiiid- 
mediated TEM-I p-lactaniase (PI 5.4), J chromo\oinaliy medixed 
p-lactaniasc of pI 7.9, and the presumptive chromosomal ceph.ilo- 
spoririase of pI 9.4. Chromosoiiial I)NA of  the strain was digected 
with HirrdlIl and ligated into the Hitdl11 s ~ t e  of pBGSIX-. Recon- 
biiiant plasmids were introduced into E. iolr TG1 by transformation, 
and colonies were selected on LB agar plates \upplemented with 
ampicillin and kanainycin. Three transforii~aiits were obtained har- 
boring a n  identical recombinant plasmid with an insert of 2.2 kbp. 
IEF of the transformants showed one band dt pl 9.4. The mtihiotic 
protile of the transformants \howed resistance to ~nioxycillin, 
~nioxycilliii-clavulanatc, cephalotin, cefiiroxirne, ccfotaxiiiic, a n d  
ceftazidiiiie. The entire 7.2-kbp fragment was sequenced md only 
one open reading frame was detected. It was 1 152 bp long, m d  coded 
for one 3x3 amino arid protein. The deduced peptide sequciice 
contained motif\ found in serine p-Iactamases. The  protein revealed 
siniilarities (35-42'K) with other AnipC p-lactaiiiasc\. By P<:li and 
using internal aniyC primers, the ~ I W J J C  g m c  wcis iietecteci in 
genetically unrelated '4 baumaiinii strains (REI'-PCI<) 
Conclusions: From a iiiultiresistant z4, huirmunrrii stran the mpC 
gene was cloned, sequenced and analyzed for the first tiiiie. This 
finding will undoubtedly contribute to the delineation of the role of 
Amp<: p-lactamase in P-lacuiii resistance of .4. bairnrnnirii. 
Viral infections (except HIV) 
Combination therapy with interferon and 
ribavirin in patients with chronic hepatitis C 
without virologic response after 2 months of 
interferon therapy: preliminary results 
E Lunel, D. Vitour, C. Payan, The Fontevraud Study Group. 
Luboratuire de Borterio- 1 Trulqje, CHC An'qcr3, .Jn<yrs, Frairrr 
Objectives: It has been deinoiistrated that interferon-alpha (IFN) 
therapy is less efficient in  patients with chronic hepatitis C infected 
by a genotype 1 or 4 or those having a high pretreatment viral load. 
The present study reports preliminary result5 of .idapted ther.ipy 
regarding the genotype and the viral load 
Patients and methods: Inclusion criteria were a7 follows: liver 
biopsy-proven chronic hepdtitis C,  ALT above the upper liniit of 
normal range at least twice in the last h months; m infection by 
genotype 1 or 4 (LiPA 11, Iiinogenetics) or pretreatment viral load 
(bDNA 2.0, Chiron) 3 Y l(1" eq/nil; no HUV or HIV infectionc; no 
decoiiipensated rirrhosis; no previous IFN treatnient; informed 
consent. Patients were followed for biological and biochemical 
parameters every month. All pxiciits receivcd 0 MIU of IFN twice 
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a week for 2 months. Detection of HCV R N A  was performed using 
Amplicor (Roche) after 2 months (M2) of therapy. Ribavirin was 
given with IFN after 3 months of therapy at a dosage of 1000- 
1200 nig/day in patients with detectable HCV R N A  at M2. Patients 
with negative HCV RNA still received IFN (MIU twice a week) for 
9 months. HCV RNA was searched for at M4 in patients receiving 
ribavirin and at M6 in all patients 
Results: One hundred and thirty-nine patients were included. 
Sixty-eight patients (49%) had detectable HCV R N A  at M2 and 
received combination therapy with ribavirin at M3. Sixteen (61%) of 
these patients had normal ALT levels. At M6, results were available 
in 86 patients (44 receiving ITN alone, 42 receiving IFN and 
ribavirin). Forty-two of forty-four patients (95%) receiving IFN 
treatment alone remained HCV R N A  negative. Twenty-two of 
forty-two patients (52%) receiving combination therapy became 
HCV R N A  negative. The majority of these patients (80%) had 
normal ALT levels at M2 
Conclusion: Thesc preliminary results show that combination 
therapy with ribavirin seem5 to enhance both biochemical and 
virologic primary response in patients who do not respond to inter- 
feron alone. The long-term response needs to be further evaluated 
wl Efficiency of IFN-alpha in the treatment of 
acute hepatitis C 
T. Tserttvadze, L. Sharvadze, T. Shartava, N. Gochitashvili, 
R. Gvetadze, M. Zarandia, GeorXian AIDS and Clinical Immunology 
Research Center, Tbilisi, CeoEia 
Objective: To evaluate the efilciency of IFN-alpha in the treatment 
of acute hepatitis C 
Methods: Nineteen male patients with acute hepatitis C aged 
19-55 were enrolled. Among them, 10 patients (first group) were 
treated with IFN-alpha, and nine patients (second group) were 
observed without treatment. Acute hepatitis C was diagnosed by the 
following criteria: (1) high level of ALT (2) high concentration of 
anti-HCV core IgM; (3) absence of antibodies against non-structural 
proteins of HCV (NS-4); (4) high level of HCV RNA. Diagnosis 
was supported by epidemiologic data. HCV antibodies were detected 
by ELISA and RIBA methods, and seruni HCV RNA by qualitative 
and quantitative PCR methods. The treatment regimen was as 
follows: IFN-alpha 5 nlln IU for 5 consecutive days, then IFN-alpha 
5 mln IU two times a week for 3 months. The monitoring of HCV 
R N A  was performed at baseline, after 7 days of treatment initiation 
and at months 1, 2 and 3 
Results: After 3 months of treatment, normal ALT levels were 
observed in eight patients (80%) and negative HCV RNA in nine 
patients (90%) among the first group of patients. Among the second 
group of patients, normal ALT levels were observed in three patients 
(33%) and negative HCV RNA in four patients (44%) 
Conclusions: IFN-alpha seems to be promising in the treatment 
of acute hepatitis C. However, to evaluate the durability and stability 
of the achieved results and the influence of therapy on the persistence 
of HCV, long-term observation is required 
ml Anti-HBc alone: association with hepatitis C 
virus co-infection 
G. Greub, P.C. Frei. Division of Immunology and Alletgy, Centre 
Hospitalier Uniuersitairr Eudois, Lairsanne, Switzerlarrd 
Objectives: Subjects with antibodies against hepatitis C core antigen 
(aHBc) as the only serologic marker for hepatitis B virus (HBV) 
infection (=anti-HBc alone) were found to be often infected with 
hepatitis C virus (HCV) (Jild et al. Individuals with antibodies against 
hepatitis B core antigen as the only serological marker for hepatitis B 
infection: high percentage of carriers of hepatitis B and C virus. J 
Hepatol 1995; 23:14-20). The aim of the present study was to 
confirm this observation and to assess the impact of HCV infection 
on aHBs level 
Methods: All samples with positive aHBc and submitted for HCV 
EIA between 1 January 1994 and 9 February 1998 were classified 
according to their serologic pattern into three groups: aHBc alone, 
AgHBs+ and aHBs+. The seroprevalence of HCV was compared 
using the Fisher exact test. aHBs levels were compared in view ofthe 
HCV serology 
Results: O f  972 samples positive for aHBc, 532 (55%) had anti- 
HBs, 241 (25%) were chronic carriers ofHBs antigen and 199 (20%) 
were aHBc-alone-positive subjects. The latter serologic pattern was 
found more frequently in HCV subjects: 
Conclusions: We confirm that aHBc-alone subjects are more 
ohen seropositive for HCV than anti-HBc carriers who also possess 
anti-HBs or HBsAg. Moreover, HCV-positive subjects with anti- 
HBs had a lower level of aHBs than HCV-negative subjects 
wl Hepatitis E virus infections in patients with 
acute non-A-D in southern Spain 
M.S. Garcia-Valdivia, M.C. Gutierrez, M.T. Perez-Gracia, 
M.C. Ybarra, F. Galan, M.A. Rodriguez-lglesias, Uniuersiry 
Hospital, Laboratory of Microbiology, Puerto Real, Spain 
Objective: To evaluate the importance of hepatitis E virus (HEV) 
infection in our area by studying patients with hepatitis signs (ALT 
increased) and negative viral hepatitis markers (hepatitis A-D) 
Methods: In a period of 3 months, 35 sera were selected from 
patients to have negative serologic markers for hepantis A, B, C or 
D. Anti-HEV IgM antibodies were detected by enzyme immnnoassay 
(EIA) (BioElisa HEV IgM, Biokit). HBs antigen and anti-HAV IgM 
and anti-HCV antibodies were detected by EIA (AxSym, Abbott), 
and HCV R N A  by RT-PCR (Amplicor, Roche) 
Results: Five sera (14.2%) were positive for anti-HEV IgM. 
However, HBsAg, anti-HAV IgM, anti-HCV and HCV R N A  were 
not detected 
Conclusions: We found an unexpected number of cases com- 
pared with prevalence studies in Spain. Nevertheless, in bordering 
regions, such as Morocco, HEV infection is endemic. It is remarkable 
that this study was done between July and September and HEV 
infection has been related to contaminated water and shellfish 
ingestion, with increased risk in these months. HEV can be an 
important agent of acute hepatitis in our area, with seasonal 
predominance in the summer, and it will be necessary to perform a 
follow-up of at least 1 year for to check this fact. 
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(o1001 TTV infection during chronic hepatitis C 
I? Trimoulet, V De Ledinghen, PH.  Bernard, t! Merel, 
I? Couzigou, HJ.A. Fleury, Cliu Pdlegrin, Laborafoire dr virologic, 
Bordrnux, France 
Objectives: The  pathogenic role of TTV is not well known, iii 
particular during chronic hepatitis C (CHC) infection. We investi- 
gated the presence of T T V  in patients with CHC and compared 
patient characteristics before treatment in TTV-positive and TTV- 
negative groups 
Methods: Between November 1996 and April 1998, 90 patients 
were treated with interferon -2a (IFN). Inclusion criteria were 
chronic cytolysir, anti-HCV and H C V  R N A  positivity, and sero- 
negativity for HBV and HIV markers. TTV DNA was amplified by 
nested PCK with TTV-specific primers derived from two conserved 
regions of viral genome. P C R  products were analyzed by agarose gel 
electrophoresis. Statistical analysis was performed using the Mann- 
Whitney test 
Results: TTV DNA was detected in 12 patients (13.3%). There 
were no statistical differences in ternis of age, sex ratio, HCV disrasc 
duration, ALT, histologic score, HCV R N A  load or genotype 
between TTV-positive and TTV-negative patients. However, 
sporadic contamination or absence of risk factors are more frequently 
found in the TTV-positive group (33.3% versus 8.9%, and 25% versus 
10.2%). re5pectively). Loss of HCV K N A  at week 12 of IFN therapy 
was also associated with absence of  TTV D N A  before treatment 
(16.6% in TTV positive versus 40.3% in TTV negative) 
Conclusion: The  severity of liver disease seenis not to be 
influenced by TTV co-infection during CHC. Among these 
patients, the role of TTV in the long-term response to IFN needs to 
be investigated because of a demonstrated relationship between the 
success of IFN therapy in C H C  and the absence of TTV DNA. 
101011 Prophylaxis of intravenous immunoglobulin 
and acyclovir in newborn infants with perinatal 
maternal varicella 
Y.C. Huan, T.Y. Lin, Y.J. Lin, R.I. Lien, Y.H. Chou. C h a q  Gun2 
Childreii 's Hospital and Chatice Guwq Uuiwrsity, Cullqe of Medicine, 
Taoyunu , Taiiuau 
Object: Maternal chickenpox around the time of delivery can cause 
severe and even fatal illness in the newborn but an effective preventive 
method has not been established yet. We proposed that a combination 
of intravenous immunoglobulin (IVIG) and acyclovir (ACV) 
intravenously could effectively prevent perinatal varicella 
Study design: Twenty-four newborn infants whose mothers had 
varicella rash within 14 days before and after delivery were included. 
Sixteen infants whose mothers' rash appeared within 7 days beforc 
and 5 days after delivery were categorized as an at-risk group and 
received IVIG 500 mg/kg alone administered soon after birth or 
postnatal contact, or acyclovir 5 mg/kg 8-hourly intravenously for ;I 
total of 5 days starting from 7 days after maternal rash, as prophylactic 
medications 
Results: Half of four infmtc receiving WIG alone developed 
clinical varicella. None of 10 infants receiving both IVIG and ACV 
contracted varicella. One  infant receiving ACV alone had no 
varicella vesicles, either. Three of eight infants in the not-at-risk 
group had undetectable varicella-zoster virur antibody on  admission 
and developed clinical varicella subsequently 
Conclusion: The  combination of IVIG given soon after birth and 
prophylactic ACV intravenously administered 7 days after niaternal 
rash can etfrctively prevent perinatal varicella 
(01021 Identification of human papillomavirus 
genomic sequences in male dysplastic genital 
lesions 
C. Dianzani', M. Iinperi', A. Pierangeli', S. Calvieri', 
A.M. Degener'. 'Iustitute qf Dermatolo'ey, 'I1 Chair !f Krolo~,xy, 
Dc,pnrtment o j  Cellular and Developmental Bi01oj3~, Univcmity of Ron~e, 
Italy 
The  presence of human papillomavirus (HPV) D N A  in diseases of 
the lower genital tract has been frequently reported. The  HPVs are 
classified into different groups according to their oncogenicity (low 
and high risk of carcinogenesis). Usually, type 6 and 11 HI'V are 
found in genital condylomata, while type 16 and 18 HPV are 
considered to carry a high risk and are associated with genital cancer. 
Several biopsies from different male anogenital lesions (condylomata 
acuminata, Uuschke-Lowenstein tumours, Bowen papuloris, leuko- 
plakia of the glans, scrota1 lymphangionia, penile horn) were analyzed 
by P C R  in order to reveal the presence of all HPV DNA genotype\ 
usually associated with genital lesions 
Total geiiomic DNA extracted from the biopsies was analyzcd by 
two different PCRs primed with two pairs of primers generating 
450- and 550-59.5-bp fragments from the late (Ll) and early (El )  
regions of the HPV genome. The El-PCR allows the specific 
amplification of sequences from genotypes of HPV 6,11,16,18, 31 
and 33. Using the Ll primers it is possible to detect about 45 HPV 
genotyper. DNA products digested with different reytriction enzymes 
give peculiar pattern5 that can be used to identiiy the precise HPV 
genotype present in the lesion. In some cases the DNA PCR product 
was automatically sequenced and the sequence was compared with 
those contained in Genebank. O u r  data reveal a high prevalence of 
type 6/11 HPV in acrociation not only with benign genital lesions 
(87% in genital condylomata), but also with malignant invasive 
neoplasias, such as verrucous carcinoma, in which the DNA ofa low- 
risk HPV genotype was unexpectedly identified. 
101031 Screening and typing of genital HPV infection 
in HIV-positive women 
M. Cupic, A.  Knezevic, L.J. Petrlcevic, N. Kuljic-Kapulica, 
J. Ranin, D.J. Jeftovic, I. Curguz, M. Bujko, Institute ~qMirrobiolqqy, 
Dcp,nrhuruf Virulqy,  Br[qrade, ki4qoslovia 
Advances in virology and epidemio1ogic research have increawd 
recognition of the clinical importance of human papillomavirus 
(HPV) infection, especially in imn~unocompron~ised conditions such 
as HIV infection (AIDS). It seems that there are tight connections 
between the numbei- of CD4 T-lymphocytes, the presence of genital 
HPV infection and the occurrence of cervical cancer among HIV- 
positive women. The aim of this study was to investigate the presence 
of HPV in ccrvical smears of 29 HIV-positive women (screcning) and 
to identify the most common HPV types (6/11, 16/18, 31/33/35) 
involved in genital HPV infection 
For screening and typing of genital HPV infection, we used the 
method of HPV DNA hybridization in situ 
The  screening results showed that 9 of 29 HIV-positive women 
were HPV positive (31%). The HPV typing revealed that six of  nine 
HPV-positive women were 6/11, 16/18 positive, and two were 
31/33/35 positive. The  associated infec-tion with two HPV types 
(6/11, 16/18) was found in one patient, and all three types were 
found in two HIV-positive women 
From the results, we conclude that the presence of genital HPV 
infection among HIV-positive women is frequent. The early 
detection of genital HPV infection plays an important role in the 
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prevention of cervical dysplasia and cancer, and also in the control of 
HIV infection 
[0104) Oral GS4104 in the treatment of naturally 
acquired influenza is effective and benefits 
health and activity status 
A. Osterhaus, F. Aoki, Y. Wegmiiller, H. Jackson, L. Huson, 
P. Ward. Erasmus University, Hofft Afdeling Virologie, Rotterdam, The 
Netherlands 
Objectives: To evaluate the efficacy of GS4104 (Ro64-0796), the 
prodrug of GS4071, a potent and selective neuraminidase inhibitor 
for the treatment of naturally acquired influenza infection and its 
impact on health and activity status 
Methods: Healthy non-immunized adults aged 18-65 years with 
a temperature of 38T and at least one respiratory and one consti- 
tutional symptom were randomized within 36 h of symptom onset 
to receive oral GS4104 75 mg or 150 nig or placebo (P) b.i.d. for 5 
days. The primary endpoint of this placebo-controlled, double-blind 
study was time to alleviation of illness in influenza-infected subjects. 
Secondary outcomes included symptom score AUC and the impact 
on health and activity status 
Results: O f  719 evaluable subjects, 475 (66%) had confirmed 
infection. Duration of illness was reduced by 30% in both treatment 
arms compared with P (P/75/150: 116.5, 87.4 (p=0.17), 81.8 h 
(p<0.007)). Treatment within 24 h of symptom onset reduced 
duration of illness by 40%. Severity of illness was reduced and the 
proportion of subjects remaining febrile after 36 h was reduced by 
60% compared with P. Oral GS4104 was associated with significantly 
better health status, daily performance and quality of sleep compared 
with P. This improvement was observed as early as 24 h after initiating 
therapy. Transient gastrointestinal effects were slightly more common 
in the active drug arms, and discontinuations were similar in all three 
dose groups 
Conclusions: Early treatment of acute influenza with oral 
GS4104 reduces both duration and severity of influenza symptom 
burden, is well tolerated, and significantly impacts on patients' overall 
health and activity status. 
Lower respiratory tract infection 
LO1 05 I Community-acquired lower respiratory tract 
infections in the elderly: a prospective study 
J. Flamaing', M. Van Ranst', W.E. Peetermans3. 'Division of 
Geriatric Medicine, 'Dqmrtment of VirologJ, 'Division of" General 
Internal Medicine, Katliolieke Universiteit Leuven, Leuven, Belgium 
Objectives: To determine the causes of lower respiratory tract 
infections (LRTIs) in elderly subjects (69 years of age) admitted to an 
acute geriatric ward during the winter of 1997-98 
Methods: Standard sputum and blood cultures for bacteriology 
A nasopharyngeal swab for respiratory syncytial virus (RSV) antigen 
detection and RSV, influenza, parainfluenza and adenovirus culture 
was obtained. Acute and convalescent sera for these viruses was 
obtained as well as for Mycoplasma pneumoniae and Chlamydia 
Results: One hundred and sixty-five elderly subjects (mean age 
82 years) were admitted with a LRTI, including 89 pneumonias 
(54%), 52 cases ofbronchitis (31.5%) and 24 exacerbations ofchronic 
obstructive pulmonary disease (14.5%). The overall mortality was 
13.3% (22/165). A definite diagnosis was possible in 63 patients 
(38.2%) (6 RSV, 46 influenza, and 2 parainfluenza infections, 
1 Mycoplasma pneumoniae infection, 6 Streptococcus pneumoniae 
bacteremias, 1 Staphylococcus aureus bacteremia,l Gram-negative 
sepsis). A positive nasopharyngeal swab was obtained in 39.7% of 
patients (25163, 24 influenza, 1 RSV). Serology contributed to the 
diagnosis in 47.6% (30/63), the nasopharyngeal swab in 4.7% (3/63) 
and both in 34.9% (22/63). A possible pathogen was identified in 27 
of 79 (34.2%) by sputum culture. A definite or possible cause could 
be established in 54.5% of the study population (90/165). Within 3 
days after admission, a definite diagnosis could be established in 20% 
(331165) and a definite or possible diagnosis in 36.4% (60/165). The 
nasopharyngeal swab contributed to early dagnosis in 75.7% 
Conclusions: The causes of LRTI in the elderly remain difficult 
to document. A nasopharyngeal swab can make a major contribution 
to the early etiologic diagnosis of viral LRTI in community-dwelling 
elderly subjects. 
1- Persistent adenoviral infection and chronic 
obstructive bronchitis in children-is there a 
link? 
M. Pichler', P. Ahrens', H. Schmidt', G. Herrmann4 , S .  Zielen. 
'University of Bonn, 'Zentmm der Kinderheilkunde, 3Zentmm der 
Radiolofie, 4Zentrum der Pathologie, Urziversity of Frankfurt, 
FrankfudM, Germany 
Objectives: To study the prevalence of persistent adenoviral 
infections in children with chronic airway obstruction 
Methods: Chronic obstructive bronchitis with inadequate res- 
ponse to inhaled steroids and bronchodilator therapy is a rather rare 
disorder in children. Persistence of an adenoviral infection has been 
described as a possible cause of unremitting airway obstruction. We 
studied a group of 10 children with the clinical feature of chronic 
bronchial obstruction. HR-CT was performed and typically showed 
hyperinflation and ground-glass-like opacities. All children under- 
went either bronchoscopic transbronchial or open lung biopsy. 
Biopsy specimens were stained with monoclonal antibodies detecting 
adenoviral antigens and analyzed at the light-microscopic level. BAL 
fluid was cultured for adenovirus and antigen detection tests were 
performed 
Results: Whereas some children had a history of proven adeno- 
viral infection at the onset of disease or showed high serologic titers 
of anti-adenoviral antibodies, in none of the cases could persistence 
of adenovirus be shown 
Conclusions: We conclude that adenoviral infection might act as 
a starter of chronic obstructive bronchitis in children, but that patho- 
genetic mechanisms other than persistent infection must be 
responsible for the disease becoming chronic 
101071 Detection of Mycoplasma pneumoniae in 
children with wheezing 
S .  Esposito, E Blasi', L. Fusetti, C. Arosio', P. Tarsia', N. Morelli', 
L. Allegra', N. Principi. Paediatric Department l y  L. Sacco Hospital, 
Institute of Respiratory Diseases, IRCCS Ospedale Maaiore, University 
ofMilan, Italy 
Objective: To evaluate the role of Mycoplasma pneumoniae infection 
in children with wheezing 
